Model Informed Precision Dosing of Oral Ibuprofen for Treatment of Persistent Patent Ductus Arteriosus: A Pilot Randomized Controlled Feasibility Trial (MIPD-PDA)

NCT07143201 Phase 2 RECRUITING

Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even death if it remains open and large. When closure of PDA is needed, doctors make every attempt to do it as soon as possible. Ibuprofen is the best drug to close the PDA, but it only works for 50% of small newborns. The investigators have shown before that small newborns handle ibuprofen differently and the amount of active ibuprofen that reaches their blood can be very unpredictable. Studies have shown if enough ibuprofen reaches the body, it can close the PDA. Therefore the investigators designed this study to see whether it is possible to give each newborn the right amount of ibuprofen that their body needs to close the PDA. The investigators will compare two ways to give ibuprofen in a small number of newborns: 1 - standard amount of ibuprofen to everyone, which is the usual care or 2 - ibuprofen doses that will be changed based on how much active ibuprofen has reached the body and how well the newborn's PDA is closing. The investigators will then compare the number of PDAs closed in each group and closely monitor any possible challenges for this new practice. By doing this project, the goals can be summarized as below: A. Primary goal: To determine if it is feasible to successfully run a larger study in the future. B. Secondary goals 1. To assess how well and how safely the personalized (MIPD) method works, using a tool called WAPPS-PDA to guide dosing. 2. To compare the effectiveness and safety of the personalized method with standard ibuprofen dosing. 3. To identify drug levels in the blood (Cmin, AUC0-24, AUC0-72) that are associated with complete, partial, or no response to treatment.

Details

Lead sponsor	Hamilton Health Sciences Corporation
Phase	Phase 2
Status	RECRUITING
Enrolment	26
Start date	2024-07-04
Completion	2027-07

Conditions

• Patent Ductus Arteriosus
• Preterm

Interventions

• Standard Dose - Ibuprofen oral suspension
• Precision Dose - Ibuprofen oral suspension

Primary outcomes

• Recruitment Feasibility — From intial dose to 96 hours after.
  Feasibility will be assessed by the ability to randomize at least 15% of all eligible patients during the study period.
• Timeliness of PK Sample Result Availability — From initial dose to 96 hours after
  Feasibility will be assessed by the ability to obtain results for at least 80% of pharmacokinetic (PK) samples within 4 hours of sample collection.
• Timeliness of Top-up Dosing Data for Intervention Arm — From initial dose to 96 hours after
  Feasibility will be assessed by the ability to generate dosing data for top-up administration within 14 hours of the previous dose in at least 80% of subjects in the intervention arm.
• Timely Completion of Daily Targeted Neonatal Echocardiogram (TnEcho) — From initial dose to 96 hours after
  Feasibility will be assessed by the ability to perform daily TnEcho within 4 to 8 hours prior to the next scheduled dose in at least 80% of subjects.
• Timely TnEcho Scoring and Model-Informed Precision Dosing (MIPD) Recommendation — From initial dose to 96 hours after
  Feasibility will be assessed by the ability to score the TnEcho, assign responsiveness grouping, and provide the MIPD recommendation for the second and third doses of oral ibuprofen within 24 hours of the previous dose in at least 80% of subjects.

Countries

Canada